CAJ | 학술논문

目的：观察厄贝沙坦对老年非ST段抬高型心肌梗死(NSTEMI)者血清肝细胞生长因子(HGF)水平的影响。方法选择2013年10月~2014年5月哈尔滨医科大学附属第四医院老年NESTMI患者38例，将入选患者中因各种原因不能服用厄贝沙坦的17例患者作为对照组，余21例为药物组。对照组给予硝酸酯药物、β受体阻滞剂、阿托伐他汀、拜阿司匹林、低分子肝素等常规治疗；药物组在此基础上给予常规治疗联合厄贝沙坦(150 mg/d)。分别于治疗前、治疗后第7天、治疗后第14天检测两组患者血清超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)；采用酶联免疫吸附试验检测血清中HGF含量。结果治疗后第14天时药物组血清hs-CRP及Hcy水平均较治疗前明显降低(P<0.05)，且明显低于对照组(P<0.05)；治疗后第7天两组患者血清HGF水平明显高于治疗前(P<0.05)，但药物组明显低于对照组(P<0.05)；两组患者治疗后第14天时HGF水平均较治第7天下降(P<0.05)，但两组组差异无统计学意义(P>0.05)。结论老年非NSTEMI患者应用厄贝沙坦2周时可使血清中hs-CRP、Hcy水平明显下降，厄贝沙坦可降低老年NSTEMI患者血清HGF水平。
목적：관찰액패사탄대노년비ST단태고형심기경사(NSTEMI)자혈청간세포생장인자(HGF)수평적영향。방법선택2013년10월~2014년5월합이빈의과대학부속제사의원노년NESTMI환자38례，장입선환자중인각충원인불능복용액패사탄적17례환자작위대조조，여21례위약물조。대조조급여초산지약물、β수체조체제、아탁벌타정、배아사필림、저분자간소등상규치료；약물조재차기출상급여상규치료연합액패사탄(150 mg/d)。분별우치료전、치료후제7천、치료후제14천검측량조환자혈청초민C반응단백(hs-CRP)、동형반광안산(Hcy)；채용매련면역흡부시험검측혈청중HGF함량。결과치료후제14천시약물조혈청hs-CRP급Hcy수평균교치료전명현강저(P<0.05)，차명현저우대조조(P<0.05)；치료후제7천량조환자혈청HGF수평명현고우치료전(P<0.05)，단약물조명현저우대조조(P<0.05)；량조환자치료후제14천시HGF수평균교치제7천하강(P<0.05)，단량조조차이무통계학의의(P>0.05)。결론노년비NSTEMI환자응용액패사탄2주시가사혈청중hs-CRP、Hcy수평명현하강，액패사탄가강저노년NSTEMI환자혈청HGF수평。
Objective To investigate the effects of Irbesartan on hepatocyte growth factor (HGF) in elderly patients with non-ST-elevation myocardial infarction (NSTEMI). Methods 38 elderly patients with NSTEMI from October 2013 to May 2014 in the Fourth Afiliated Hospital of Harbin Medical Universit were selected, and 17 cases who couldn't take Irbesartan were as control group, the others were as the drug group. The control group was given conventional therapy, such as nitric acid ester, β-receptor blocker, atorvastain, bayaspirin, low molecular heparin, and the drug group was given conventional therapy combined with Irbesartan (150 mg/d). The levels of serum hs-CRP, Hcy of two groups were measured before and 7, 14 days after treatment respectively, and the levels of HGF were detected by ELISA,. Results After treatment 14 days, the levels of hs-CRP and Hcy were significant decreased than those before treatment and the control group (P<0.05);after treatment 7 days, HGF in two groups was significantly higher than those before treatment (P< 0.05), while the drug group was less obviously higher than the control group (P< 0.05); after treatment 14 days HGF in two groups was significantly lower than those after treatment 7 days (P< 0.05), and there was no statistically significant (P>0.05). Conclusion After 2 weeks treatment with Irbesartan, the levels of serum hs-CRP and Hcy in el-derly patients with NSTEMI can be reduced significantly, Irbesartan can reduce the level of serum HGF in elderly pa-tients with NSTEMI.